MX2019014876A - Compuestos heteroaromaticos como inhibidores de vanina. - Google Patents
Compuestos heteroaromaticos como inhibidores de vanina.Info
- Publication number
- MX2019014876A MX2019014876A MX2019014876A MX2019014876A MX2019014876A MX 2019014876 A MX2019014876 A MX 2019014876A MX 2019014876 A MX2019014876 A MX 2019014876A MX 2019014876 A MX2019014876 A MX 2019014876A MX 2019014876 A MX2019014876 A MX 2019014876A
- Authority
- MX
- Mexico
- Prior art keywords
- heteroaromatic compounds
- compounds
- vanin
- inhibitors
- vanin inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención abarca los compuestos de la Fórmula (I) (ver Fórmula) en donde los grupos A y B se definen en la presente, que son adecuados para el tratamiento de enfermedades relacionadas con vanina, y los procesos para fabricar estos compuestos, las preparaciones farmacéuticas que contienen estos compuestos y sus métodos de uso.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762518106P | 2017-06-12 | 2017-06-12 | |
| PCT/EP2018/065140 WO2018228934A1 (en) | 2017-06-12 | 2018-06-08 | Heteroaromatic compounds as vanin inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019014876A true MX2019014876A (es) | 2020-02-13 |
Family
ID=62631060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019014876A MX2019014876A (es) | 2017-06-12 | 2018-06-08 | Compuestos heteroaromaticos como inhibidores de vanina. |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10364255B2 (es) |
| EP (1) | EP3638680B1 (es) |
| JP (1) | JP6880243B2 (es) |
| KR (1) | KR102607934B1 (es) |
| CN (1) | CN110770242B (es) |
| AR (1) | AR112086A1 (es) |
| AU (1) | AU2018285131B2 (es) |
| BR (1) | BR112019021703A2 (es) |
| CA (1) | CA3066946A1 (es) |
| CL (1) | CL2019003515A1 (es) |
| CO (1) | CO2019013823A2 (es) |
| DK (1) | DK3638680T3 (es) |
| EA (1) | EA039223B1 (es) |
| ES (1) | ES2927021T3 (es) |
| HU (1) | HUE060597T2 (es) |
| IL (1) | IL271104B (es) |
| MA (1) | MA49374A (es) |
| MX (1) | MX2019014876A (es) |
| PE (1) | PE20200340A1 (es) |
| PH (1) | PH12019502693A1 (es) |
| PL (1) | PL3638680T3 (es) |
| TW (1) | TW201920196A (es) |
| WO (1) | WO2018228934A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20200340A1 (es) * | 2017-06-12 | 2020-02-14 | Boehringer Ingelheim Int | Compuestos heteroaromaticos como inhibidores de vanina |
| CA3104928A1 (en) | 2018-08-13 | 2020-02-20 | F. Hoffmann-La Roche Ag | New heterocyclic compounds as monoacylglycerol lipase inhibitors |
| SG11202101749VA (en) * | 2018-08-28 | 2021-03-30 | Boehringer Ingelheim Int | Heteroaromatic compounds as vanin inhibitors |
| WO2020114943A1 (en) | 2018-12-03 | 2020-06-11 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as vanin inhibitors |
| CR20220104A (es) | 2019-09-12 | 2022-04-20 | Hoffmann La Roche | Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de magl |
| US20230107927A1 (en) | 2020-02-28 | 2023-04-06 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005035524A1 (en) * | 2003-10-09 | 2005-04-21 | Abbott Laboratories | Pyrrolidinyl urea derivatives as angiogensis inhibitors |
| JP2018516254A (ja) * | 2015-05-29 | 2018-06-21 | ファイザー・インク | バニン１酵素の阻害薬としての新規なヘテロ環化合物 |
| CA3030381A1 (en) * | 2016-07-14 | 2018-01-18 | Pfizer Inc. | Pyrimidine carboxamides as inhibitors of vanin-1 enzyme |
| PE20200340A1 (es) * | 2017-06-12 | 2020-02-14 | Boehringer Ingelheim Int | Compuestos heteroaromaticos como inhibidores de vanina |
-
2018
- 2018-06-08 PE PE2019002531A patent/PE20200340A1/es unknown
- 2018-06-08 CN CN201880039562.3A patent/CN110770242B/zh active Active
- 2018-06-08 DK DK18731766.4T patent/DK3638680T3/da active
- 2018-06-08 KR KR1020197038628A patent/KR102607934B1/ko active IP Right Grant
- 2018-06-08 CA CA3066946A patent/CA3066946A1/en active Pending
- 2018-06-08 MA MA049374A patent/MA49374A/fr unknown
- 2018-06-08 ES ES18731766T patent/ES2927021T3/es active Active
- 2018-06-08 HU HUE18731766A patent/HUE060597T2/hu unknown
- 2018-06-08 BR BR112019021703-7A patent/BR112019021703A2/pt unknown
- 2018-06-08 AU AU2018285131A patent/AU2018285131B2/en active Active
- 2018-06-08 EA EA202090014A patent/EA039223B1/ru unknown
- 2018-06-08 EP EP18731766.4A patent/EP3638680B1/en active Active
- 2018-06-08 WO PCT/EP2018/065140 patent/WO2018228934A1/en unknown
- 2018-06-08 US US16/003,252 patent/US10364255B2/en active Active
- 2018-06-08 MX MX2019014876A patent/MX2019014876A/es unknown
- 2018-06-08 PL PL18731766.4T patent/PL3638680T3/pl unknown
- 2018-06-08 JP JP2019566724A patent/JP6880243B2/ja active Active
- 2018-06-11 TW TW107119946A patent/TW201920196A/zh unknown
- 2018-06-11 AR ARP180101573A patent/AR112086A1/es unknown
-
2019
- 2019-05-13 US US16/410,037 patent/US20190263828A1/en not_active Abandoned
- 2019-11-28 PH PH12019502693A patent/PH12019502693A1/en unknown
- 2019-12-02 IL IL271104A patent/IL271104B/en unknown
- 2019-12-02 CL CL2019003515A patent/CL2019003515A1/es unknown
- 2019-12-09 CO CONC2019/0013823A patent/CO2019013823A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK3638680T3 (da) | 2022-09-05 |
| EA039223B1 (ru) | 2021-12-20 |
| US20180354968A1 (en) | 2018-12-13 |
| PL3638680T3 (pl) | 2022-12-19 |
| TW201920196A (zh) | 2019-06-01 |
| MA49374A (fr) | 2021-04-21 |
| PE20200340A1 (es) | 2020-02-14 |
| KR102607934B1 (ko) | 2023-12-01 |
| AR112086A1 (es) | 2019-09-18 |
| AU2018285131B2 (en) | 2021-11-11 |
| IL271104B (en) | 2022-03-01 |
| CL2019003515A1 (es) | 2020-06-19 |
| AU2018285131A1 (en) | 2019-10-31 |
| CN110770242B (zh) | 2022-08-19 |
| PH12019502693A1 (en) | 2020-07-13 |
| CN110770242A (zh) | 2020-02-07 |
| EA202090014A1 (ru) | 2020-05-12 |
| IL271104A (en) | 2020-01-30 |
| EP3638680B1 (en) | 2022-08-10 |
| CO2019013823A2 (es) | 2020-01-17 |
| US20190263828A1 (en) | 2019-08-29 |
| HUE060597T2 (hu) | 2023-04-28 |
| JP2020522517A (ja) | 2020-07-30 |
| JP6880243B2 (ja) | 2021-06-02 |
| US10364255B2 (en) | 2019-07-30 |
| ES2927021T3 (es) | 2022-11-02 |
| EP3638680A1 (en) | 2020-04-22 |
| CA3066946A1 (en) | 2018-12-20 |
| KR20200013718A (ko) | 2020-02-07 |
| BR112019021703A2 (pt) | 2020-05-12 |
| WO2018228934A1 (en) | 2018-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY197440A (en) | Heteroamatic compounds as btk inhibitors | |
| PH12020500252A1 (en) | Compounds as modulators of ror gamma | |
| MY196909A (en) | Boronic acid derivatives and therapeutic uses thereof | |
| PH12019501985A1 (en) | Fused imidazo-piperidine jak inhibitors | |
| PH12019502693A1 (en) | Heteroaromatic compounds as vanin inhibitors | |
| MY195427A (en) | Jak Kinase Inhibitor Compounds for Treatment of Respiratory Disease | |
| PH12016501898A1 (en) | Quinoxaline derivatives useful as fgfr kinase modulators | |
| SA515360007B1 (ar) | مركبات عطرية غير متجانسة كمثبطات بروتونز تيروسين كيناز ( btk) | |
| TW201613886A (en) | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones | |
| PH12021551280A1 (en) | Heteroaromatic compounds as vanin inhibitors | |
| PH12021550269A1 (en) | Heteroaromatic compounds as vanin inhibitors | |
| MX2021006489A (es) | Compuestos heteroaromaticos como inhibidores de vanina. | |
| TR201900148T4 (tr) | Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin. | |
| PH12016502568B1 (en) | Novel heterocyclic compound | |
| MX2021006490A (es) | Compuestos heteroaromaticos como inhibidores de vanina. | |
| MX2019000542A (es) | Derivados de pirazolilaminobenzimidazol como inhibidores de jak. | |
| MX2019014436A (es) | Derivados de piridoquinazolina eficaces como inhibidores de proteina quinasa. |